Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Taysha Gene Therapies Inc TSHA

Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.


NDAQ:TSHA - Post by User

User Avatar Image
(10)
•••
  • MikeTesterX
Post by MikeTesteron Aug 02, 2024 5:42am
69 Views
Post# 36160001

Taysha Gene Therapies, Inc. (TSHA): Advancing a Promising Ge

Taysha Gene Therapies, Inc. (TSHA): Advancing a Promising Gehttps://beyondspx.com/2024/08/01/taysha-gene-therapies-inc-tsha-advancing-a-promising-gene-therapy-pipeline-for-rare-neurological-disorders/
<< Previous
Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities